ClinicalTrials.gg

Program

elinzanetant

Also written as “Elinzanetant (BAY3427080)”, “GSK1144814” and “BAY3427080”.

Its studies are mostly in Hot Flashes · Schizophrenia, led by 2 companies.

Furthest: phase 3, since Aug 26, 202124 company-led studies, 2 open or runningNext primary completion: Jan 22, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bayer212 open or runningphase 3since Aug 26, 2021Aug 3, 2016Jan 22, 2027phase 1 · NCT07762287
GlaxoSmithKline30 open or runningphase 1since Mar 4, 2010Mar 4, 2010none ahead

Also a collaborator on its studies: nerre-therapeutics-ltd and quotient-sciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 5 studies since Mar 4, 2010.

  1. Nov 25, 2020Phase 1 study in HealthyBayer · NCT04654897 · 6 enrolled · United Kingdom
  2. Apr 7, 2021Phase 1 study in Multiple Endocrine Neoplasia Type 1Bayer · NCT04845841 · 16 enrolled · Germany
  3. May 14, 20212 phase 1 studies in Multiple Endocrine Neoplasia Type 1Bayer · NCT04889287, NCT04903821
  4. Jul 5, 2021Phase 1 study in Multiple Endocrine Neoplasia Type 1Bayer · NCT04981431 · 62 enrolled · Japan
  5. Aug 26, 20212 phase 3 studies in Hot FlashesBayer · NCT05042362, NCT05030584
  6. Aug 26, 2021Phase 1 study in Multiple Endocrine Neoplasia Type 1Bayer · NCT05028608 · 16 enrolled · Germany
  7. Sep 20, 20212 phase 1 studies in Multiple Endocrine Neoplasia Type 1Bayer · NCT05061563, NCT05071729
  8. Oct 19, 2021Phase 3 study in Hot FlashesBayer · NCT05099159 · 400 enrolled · United States, Canada, Czechia and more
  9. Apr 25, 20222 phase 1 studies in Multiple Endocrine Neoplasia Type 1Bayer · NCT05351892, NCT05381142
  10. Jul 21, 20222 phase 1 studies in Multiple Endocrine Neoplasia Type 1Bayer · NCT05471817, NCT05481528
  11. Oct 17, 2022Phase 3 study in Hot FlashesBayer · NCT05587296 · 474 enrolled · Austria, Belgium, Canada and more
  12. Oct 27, 2023Phase 2 study in Sleep Disturbances Associated With MenopauseBayer · NCT06112756 · 110 enrolled · United States, Austria, Belgium and more
  13. Dec 21, 2023Phase 1 study in Multiple Endocrine Neoplasia Type 1Bayer · NCT06219902 · 64 enrolled · Canada
  14. Jul 15, 2026Phase 1 study in Vasomotor Symptoms as a Sex Hormone-dependent Disorder in WomenBayer · NCT07762287 · 100 planned · Canada

Ahead

  1. Jan 22, 2027Primary completion: phase 1 study in Vasomotor Symptoms as a Sex Hormone-dependent Disorder in WomenBayer · NCT07762287

TargetBeta

“An orally bioavailable neurokinin/tachykinin 1 receptor (NK1-receptor; NK1R; NK-1R) and NK3 receptor (NK-3R; NK3R) antagonist, that may be used to treat vasomotor symptoms in menopausal woman”NCIt, by rule
“Neurokinin 1 receptor antagonist; Neurokinin 3 receptor antagonist”ChEMBL 37, by rule

Studies

All 24 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07762287Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women · Canada1RecruitingBayerJan 22, 2027100
NCT06219902Multiple Endocrine Neoplasia Type 1 · Canada1CompletedBayerApr 15, 202464
NCT06112756Sleep Disturbances Associated With Menopause · United States, Austria, Belgium and more2CompletedBayerAug 22, 2024110
NCT05587296Hot Flashes · Austria, Belgium, Canada and more3Active, not recruitingBayerJan 29, 2024474
NCT05481528Multiple Endocrine Neoplasia Type 1 · Germany1CompletedBayerFeb 7, 202351
NCT05471817Multiple Endocrine Neoplasia Type 1 · Germany1CompletedBayerSep 20, 202220
NCT05381142Multiple Endocrine Neoplasia Type 1 · China1CompletedBayerJul 11, 202216
NCT05351892Multiple Endocrine Neoplasia Type 1 · United States1CompletedBayerJun 9, 202218
NCT05099159Hot Flashes · United States, Canada, Czechia and more3CompletedBayerJun 13, 2023400
NCT05071729Multiple Endocrine Neoplasia Type 1 · United States1CompletedBayerOct 19, 202231
NCT05061563Multiple Endocrine Neoplasia Type 1 · Netherlands1CompletedBayerDec 9, 202114
NCT05030584Hot Flashes · United States, Belgium, Bulgaria and more3CompletedBayerMar 29, 2023628
NCT05042362Hot Flashes · United States, Austria, Czechia and more3CompletedBayerJul 25, 2023396
NCT05028608Multiple Endocrine Neoplasia Type 1 · Germany1CompletedBayerOct 31, 202116
NCT04981431Multiple Endocrine Neoplasia Type 1 · Japan1CompletedBayerMar 13, 202262
NCT04903821Multiple Endocrine Neoplasia Type 1 · Germany1CompletedBayerMar 15, 202233
NCT04889287Multiple Endocrine Neoplasia Type 1 · Germany1CompletedBayerJul 23, 202116
NCT04845841Multiple Endocrine Neoplasia Type 1 · Germany1CompletedBayerJun 1, 202116
NCT04654897Healthy · United Kingdom1CompletedBayerOct 29, 20206
NCT03596762Hot Flashes · United States, Canada, United Kingdom2CompletedBayerNov 21, 2019199
NCT02865538Hot Flashes · United States2CompletedBayerMar 28, 201776
NCT01381419Schizophrenia · United Kingdom1CompletedGlaxoSmithKlineApr 1, 200921
NCT01209039Schizophrenia · United Kingdom1CompletedGlaxoSmithKlineOct 25, 200941
NCT01090440Schizophrenia · Australia1CompletedGlaxoSmithKlineOct 9, 200916

How it is read

Names in the registry

  • “Elinzanetant (BAY3427080)”, 15 entries
  • “GSK1144814”, 7 entries
  • “BAY3427080”, 2 entries
  • “Elinzanetant (BAY 3427080) treatment A”, 1 entry
  • “Elinzanetant (BAY 3427080) treatment B”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.